Humacyte arrives at its third-quarter report as a company running two very different races. Its dialysis program has rarely looked better, with a Phase 3 interim win and a supplemental filing targeted for this very month. Its commercial trauma business, the only thing generating revenue today, was essentially torn down and rebuilt over the summer. Management asked investors to wait until the second half for results. The November 10 release, due before the open, is the first real look at whether that wait is paying off.
The Street is not asking for much. Consensus calls for a loss of $0.09 per share, a meaningful improvement from the $0.14 loss a year ago and the $0.16 loss last quarter. Revenue is pegged at roughly $860,000, up about 14% from the year-ago $0.8 million. Measured against the prior quarter, though, the forecast is more demanding than it looks. Sales of the SIMVEST vessel fell to $0.4 million in the second quarter, down from $0.5 million in the first quarter and about $0.7 million in last year's third quarter. Hitting consensus would roughly double sequential revenue. Management still declines to guide trauma sales, so there is no company range to anchor that estimate. That leaves the number as an analyst bet that the new commercial team can deliver quickly.
That team is the heart of the story. After the prior commercial chief departed, the new leadership rebuilt the sales force, the strategy and the national-account function over three to four months. They conceded that the company had underestimated how much surgeon education and relationship work trauma adoption requires. They pointed to more than 20 health systems moving through value analysis committees toward adoption in the back half, and to a national-account push aimed at roughly 1,000 more hospitals. A validating report would show those approvals turning into orders, with revenue clearly back above the half-million-dollar mark and commentary pointing to repeat use rather than one-off trials. Another flat or declining quarter would suggest the reset is taking longer than promised, and would leave the second-half target looking optimistic.
Margins deserve equal scrutiny. Cost of goods jumped to $1.2 million last quarter, swollen by a $0.7 million inventory reserve, which brought reserves to $2.3 million for the first half, along with overhead from unused manufacturing capacity. Further write-downs would signal that product is expiring before it can be sold, which is a direct read on demand. Cash stood at $80.3 million at the end of June after a 25% workforce cut in May. With the dialysis launch not expected until mid-2027, the pace of cash burn and any hint of financing plans will matter as much as the loss per share.
On the clinical side, the bar is confirmation. The VO-12 data showed 91 more catheter-free days than fistulas and far lower infection rates, and management outlined a priority review request, a potential decision around May 2027 and a launch by the end of that year's second quarter. Investors should look for evidence that the pre-BLA meeting went smoothly and that the filing is on schedule or already submitted. They will also want an update on the 10-patient coronary bypass study of the CTEV product. Any slip would hit hard, since management has acknowledged the decision date could move to August even with priority review.
The market has been unforgiving. Shares have fallen about 38% since the last report, far worse than the S&P 500's 3% decline. At $0.40, the stock sits half its 200-day average and near the bottom of its post-earnings range of $0.34 to $0.75. Sentiment has warmed modestly, from about 35% bullish to 46%, which hints that some investors see the dialysis catalyst as underpriced. The central question is simple. Can trauma sales show enough life to bridge the company to a dialysis approval without leaning too heavily on the balance sheet? A clean filing plus a visible commercial rebound would keep the two-business narrative intact. Strength in only one would leave it fragile.